Novartis Five-Year Kymriah Data Show Durable Remission in Trial

Novartis Pharma AG says it has seen long-term results from the “ELIANA” clinical trial of Kymriah CAR-T cell therapy, according to a statement.

The results were seen in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.

Novartis says that for the 79 patients treated with Kymriah in this study, the five-year overall survival rate was 55%, while the median event-free survival for patients in remission within three months of infusion was 43.8 months.

To contact the reporter on this story:
Deana Kjuka in Prague at ...